Perspective Therapeutics (CATX) Cash from Investing Activities (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Cash from Investing Activities data on file, last reported at -$109.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 1868.61% year-over-year to -$109.6 million; the trailing twelve-month figure through Mar 2026 stood at -$62.8 million (up 64.58% YoY), and the FY2025 full-year result was $41.2 million, up 118.83% from the prior year.
• Cash from Investing Activities declined to -$109.6 million in Q1 2026, from $28.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $28.5 million in Q4 2025 to a low of -$138.6 million in Q4 2024.
• A 5-year average of -$19.2 million and a median of -$573000.0 in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 97261.54% in 2023 and plunged 155632.58% in 2024, its largest moves.
• Tracing CATX's Cash from Investing Activities over 5 years: stood at -$28.8 million in 2022, then jumped by 99.69% to -$89000.0 in 2023, then sank by 155632.58% to -$138.6 million in 2024, then surged by 120.59% to $28.5 million in 2025, then sank by 483.9% to -$109.6 million in 2026.
• Business Quant data shows CATX's Cash from Investing Activities at -$109.6 million in Q1 2026, $28.5 million in Q4 2025, and $14.0 million in Q3 2025.